Novel Microdevices, Inc.
Novel Microdevices, Inc. is a woman-owned, woman-led company based in Baltimore, Maryland, specializing in the development of ultra-portable, rapid, point-of-care molecular diagnostic systems. Their mission is to revolutionize infectious disease diagnostics, particularly for women’s health and under-resourced populations, by providing fast, accurate, and affordable testing solutions. Their flagship platform, Novel Dx, is designed to deliver lab-quality results in under 15 minutes, enabling immediate diagnosis and treatment at the point of care. The company is committed to addressing global health challenges, including antibiotic-resistant infections, through innovative technology and strategic partnerships.
Novel Microdevices, Inc.
101 W Dickman St Ste 300, Baltimore, MD 21230
Patents
Sample-to-answer microfluidic system and method including vertical microfluidic device and automated actuation mechanisms
2025-07-29 • US-12370544-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
2024-11-26 • US-12151239-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
2022-06-21 • US-11364495-B2
View DetailsSample processing device comprising magnetic and mechanical actuating elements using linear or rotational motion and methods of use thereof
2022-03-01 • US-11260392-B2
View DetailsWhat We Do
A proprietary, ultra-portable, point-of-care rapid molecular diagnostics system that uses PCR technology on a disposable cartridge. It delivers lab-quality results in under 15 minutes for infectious diseases such as Flu, RSV, COVID-19, and STIs. The system is battery-powered, weighs less than 4 lbs, and is designed for use in low-resource settings. It features integrated lysis, nucleic acid extraction, multiplexed targets, and cloud connectivity. The system and diagnostic assays are in development and not yet available for sale.
A next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae, with the ability to detect antibiotic-resistant strains. The device diagnoses infections in about 25 minutes from vaginal swab or urine samples. Supported by CARB-X funding.
Infectious Diseases
Key People
CEO, Co-Founder
VP, Product Development
VP, Engineering, Co-Founder
Director of Assay Development
Chief Operating Officer
Chief Medical Officer
News & Updates
Received a significant grant to establish a GMP-compliant pilot manufacturing facility for microfluidic cartridges at its Baltimore headquarters.
Received $2.68 million in follow-on funding from the NIH RADx® Tech program after achieving key milestones for its point-of-care RT-PCR platform.
Received up to $13.8 million in non-dilutive funding from CARB-X to develop rapid molecular tests for STIs, including antibiotic-resistant infections.
Andrea Pais, co-founder and CEO, recognized as one of The Baltimore Sun’s 25 Women to Watch in 2021 for her leadership in diagnostic innovation.
Novel Microdevices, Inc. has been awarded $633,757 through the Build Our Future Grant Pilot Program by the Maryland Department of Commerce to establish a GMP-compliant pilot manufacturing facility for microfluidic cartridges used in its diagnostic platform.
Profiled for the 2024 Mayor’s Awards, highlighting the company’s leadership in medical diagnostic innovation and recent NIH RADx® Tech program funding.